Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 or older, of any gender.
- People diagnosed with a specific type of breast cancer called invasive breast carcinoma of no special type, where the cancer is hormone receptor-positive and HER2-negative (confirm with trial site for exact test results).
- People whose cancer has not spread to distant parts of the body (classified as M0 under a standard cancer staging system used in 2018).
- People who have already had surgery to remove the primary breast tumour with the goal of curing the disease.
- People who have received radiotherapy after surgery, if that was recommended for them.
- People whose cancer care team (at a multidisciplinary meeting) has agreed that a combination of hormone-blocking therapy and a CDK4/6 inhibitor medication is the right treatment after surgery.
- People who started this combined hormone and CDK4/6 inhibitor treatment between June 2023 and June 2028.
- People who have not objected to taking part in the study.
- People who are enrolled in the national health insurance system.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose medical, personal, geographical, or legal circumstances may make it difficult to complete the study or to formally indicate they have no objection to taking part.
- People with locally advanced breast cancer that cannot be operated on, or with cancer that has spread to other parts of the body in a way that cannot be treated with curative intent.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Emmanuelle JACQUET, University Hospital, Grenoble
Phone: 33 0)476765451
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary objective of this study is to evaluate adherence to iCDK4/6 treatment in patients with localized hormone receptor-positive breast cancer at high risk of recurrence, within a real-world setting.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.